||5R01CA243188-04 Interpret this number
||University Of Utah
||Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival: an Integrative Approach
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer deaths in women. Compared to non-
Hispanic white (NHW) women, African American (AA) women have much poorer survival after an EOC
diagnosis, which, as we have found, may be in part due to AA women being less likely to receive standard-of-
care therapy, and more likely to have chemotherapy dose reduction, even within an equal-access healthcare
system. However, these factors do not completely explain survival disparities among AAs, and furthermore,
little is known about other groups (e.g., Hispanics and Asians/Pacific Islanders (API)), although there is some
evidence that Hispanic women also experience worse survival. Moreover, emerging evidence suggests racial
differences in molecular subtype distribution. We propose to conduct the first integrative, cells-to-society
evaluation of the interplay among multilevel factors on disparities in EOC treatment and survival outcomes.
We will assemble a cohort of ~4,600 EOC cases, including ~280 AA, ~520 Hispanic, ~730 API, and
~2,980 NHW women diagnosed at Kaiser Permanente Northern California (KPNC) between 2000 and 2023.
KPNC has longstanding electronic clinical databases, complete pathology specimen storage, long-term
retention of members, and substantial variability in sociodemographic, clinical, and neighborhood
characteristics among races/ethnicities. We will perform centralized pathology review to classify histotypes by
the recent gold standard WHO criteria, and will conduct chart review to capture data that are not available
electronically. We will examine determinants of racial/ethnic differences in treatment received, recurrence, and
survival (overall and EOC-specific), including neighborhood social stressors through linkage to data on
segregation, structural racism, ethnic enclaves, and geographic medical accessibility, health care system and
patient-level factors. In 800 women (200 each of NHW, AA, Hispanic, and API) with high grade serous EOC,
we will also characterize gene expression subtypes (to date studied almost exclusively in NHW women), to
identify whether the relative distribution of aggressive subtypes contributes to the observed survival disparities.
We will examine these factors in the context of both self-reported race/ethnicity and genetic ancestry.
Our comprehensive integrative approach to examine the interplay among patient, health care, social
contextual, and biological factors will provide unique insights into the persistent racial disparities in EOC
survival. The KPNC setting provides the opportunity to examine these factors while minimizing confounding by
the known contribution of insurance status, leveraging rich clinical databases to investigate and control for
detailed prognostic variables, and avoiding survival bias. For EOC, this proposed study is unprecedented in its
transdisciplinary nature, sample size, and multi-ethnic population, and will serve as a unique resource for
future research related to multilevel factors to reduce EOC survival disparities.
Role of neighborhood context in ovarian cancer survival disparities: current research and future directions.
, Chirikova E.
, McGuire V.
, Collin L.J.
, Dempsey L.
, Inamdar P.P.
, Lawson-Michod K.
, Peters E.S.
, Kushi L.H.
, Kavecansky J.
, et al.
American journal of obstetrics and gynecology, 2023 Oct; 229(4), p. 366-376.e8.
Neoadjuvant Chemotherapy in Ovarian Cancer: Are There Racial Disparities in Use and Survival?
, Collin L.J.
, Setoguchi S.
, Satagopan J.M.
, Buckley de Meritens A.
, Bandera E.V.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2023-02-06; 32(2), p. 175-182.
Mortality Patterns of Synchronous Uterine and Ovarian Cancers: A SEER Registry Analysis.
, Pappas L.M.
, Collin L.J.
, Vranes C.
, Trabert B.
, Doherty J.A.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022-11-02; 31(11), p. 2038-2045.